跳至主要内容
临床试验/NCT00805207
NCT00805207已完成不适用

Sex Steroids, Sleep, and Metabolic Dysfunction in Women

Washington University School of Medicine1 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
61
试验地点
1
主要终点
Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate

研究概览

简要总结

Increased plasma triglyceride concentration is a common feature of the metabolic abnormalities associated with obesity and a major risk factor for cardiovascular disease. Obesity is a major risk factor for two conditions that appear to be increasing in prevalence in women: the polycystic ovary syndrome (PCOS) and sleep disordered breathing. PCOS affects 5-8% of women. Sleep disordered breathing affects up to 10% of women. Obstructive sleep apnea (OSA) is the most common cause for sleep disordered breathing and particularly prevalent in obese women with PCOS (~50%). Both PCOS and OSA augment the increase in plasma triglyceride (TG) concentration associated with obesity, and the effects of PCOS and OSA on plasma TG concentration appear to be additive. The mechanisms responsible for the adverse effects on plasma TG metabolism are not known. The primary goal of this project, therefore, is to determine the mechanisms responsible for the increase in plasma TG concentration in obese women with PCOS and OSA. It is our general hypothesis that alterations in the hormonal milieu that are characteristic of these two conditions are, at least in part, responsible for the increase in plasma TG concentration in obese women with the conditions. Furthermore, we hypothesize that the hormonal aberrations characteristic of the two conditions are particularly harmful to obese, compared with lean, women.

The effects of PCOS on skeletal muscle protein metabolism are also not known. However, sex hormones are thought to be important regulators of muscle protein turnover suggesting that muscle protein metabolism is likely to be affected by PCOS. We will examine this by determining the effect of individual sex hormones on muscle protein metabolism and hypothesize that testosterone administration will stimulate muscle protein metabolism while estrogen and progesterone administration will inhibit muscle protein metabolism.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Women aged 18-75 years and men 45-75 years
  • Healthy lean, overweight and obese women (BMI 18-40 kg/m2) and obese men (BMI 30-40 kg/m2)
  • Obese women (BMI 30-40 kg/m2) with OSA or PCOS

排除标准

  • Pregnant, lactating, peri- or postmenopausal women will be excluded from the study because of potential confounding influences of these factors and potential ethical concerns (pregnant women)
  • Women taking medications known to affect substrate metabolism and those with evidence of significant organ dysfunction (e.g. impaired glucose tolerance, diabetes mellitus, liver disease, hypo- or hyper-thyroidism) other than PCOS and OSA
  • Severe hypertriglyceridemia (fasting plasma TG concentration >400 mg/dl)
  • Subjects with OSA who have an apnea-hypopnea index (AHI) score >30 (the total number of obstructive events divided by the total hours of sleep) will be excluded and instructed to seek medical care

研究组 & 干预措施

Progesterone - PCOS

Experimental

Women with obesity and polycystic ovary syndrome

干预措施: Progesterone (Drug)

Testosterone - premenopausal women

Experimental

Healthy premenopausal women.

干预措施: testosterone (Drug)

Continuous positive airway pressure

Experimental

Women and men with obesity and obstructive sleep apnea

干预措施: continuous positive airway pressure (Device)

Glucocorticoid

Experimental

Lean and obese healthy women, and obese men

干预措施: glucocorticoid (Drug)

Estrogen

Experimental

Postmenopausal women

干预措施: Estrogen (Drug)

control

Other

Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits

干预措施: Control (Other)

Progesterone - Postmenopausal women

Experimental

Postmenopausal women

干预措施: Progesterone (Drug)

Testosterone - Postmenopausal women

Experimental

Postmenopausal women

干预措施: testosterone (Drug)

结局指标

主要结局

Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate

时间窗: Before and at the end of interventions

VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The hepatic (liver) secretion rates of VLDL-TG was calculated by multiplying the fractional turnover rates of VLDL-TG by the of VLDL-TG concentration.

次要结局

  • Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentration(Before and at the end of the interventions)
  • VLDL-TG Plasma Clearance Rate (Means)(Before and at the end of the interventions)
  • VLDL-TG Plasma Clearance Rate (Medians)(Before and at the end of the interventions)
  • Basal, Postabsorptive Fractional Synthesis Rates of Muscle Protein Synthesis(Before and at the end of the intervention)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验